10-Q: Ashland Inc. Reports Q1 2024 Results: Sales Decline, Restructuring Impacts Earnings

Ashland Inc. reported a decrease in sales and operating income for the first quarter of fiscal year 2024, impacted by lower volumes and restructuring activities, while also highlighting a new stock repurchase program and a one-time stock grant to the CEO.

Summary

• Ashland Inc.'s sales decreased by $52 million to $473 million in the first quarter of fiscal year 2024 compared to the same period last year.
• The company's operating income was a loss of $18 million, a significant drop from the $37 million profit in the prior year.
• Net income for the quarter was $26 million, down from $40 million in the previous year.
• The decrease in sales was primarily due to lower sales volume, with a $51 million negative impact.
• Cost of sales increased by $15 million, driven by higher operating costs and accelerated depreciation of $21 million related to product line optimization.
• Selling, general, and administrative expenses decreased by $10 million, partially due to lower variable compensation expenses.
• The company's effective tax rate was a benefit of 600%, influenced by jurisdictional income mix and favorable tax discrete items of $24 million.
• Adjusted EBITDA was $70 million, a decrease from $108 million in the prior year, primarily due to lower sales and production volumes.
• Ashland repurchased 1.2 million shares of common stock for $100 million during the quarter.
• The company initiated a new foreign accounts receivable sales program in Europe, selling $102 million in receivables.
• Ashland expects second-quarter sales to be between $565 million and $585 million and adjusted EBITDA between $115 million and $125 million.
• For the full fiscal year, Ashland anticipates sales between $2.15 billion and $2.25 billion and adjusted EBITDA between $460 million and $500 million.

Sentiment

Score: 4

Explanation: The document presents a mixed picture with significant declines in sales and profitability, offset by some positive developments like the stock repurchase program and cost-cutting measures. The overall tone is cautious, reflecting the challenges faced by the company.

Positives

• Selling, general, and administrative expenses decreased by $10 million.
• The company's effective tax rate was a benefit of 600% due to favorable tax discrete items.
• Ashland expects a partial return to more typical margins during the second quarter of fiscal 2024.
• The company has a strong liquidity position with $1,036 million available including cash and the revolving credit facility.
• Ashland is in compliance with all debt agreement covenant restrictions.

Negatives

• Sales decreased by $52 million year-over-year.
• Operating income declined from a $37 million profit to a $18 million loss.
• Net income decreased from $40 million to $26 million.
• Adjusted EBITDA decreased by $38 million to $70 million.
• Cost of sales increased by $15 million due to higher operating costs and accelerated depreciation.
• The company recorded a loss on acquisitions and divestitures of $2 million.
• The Specialty Additives segment experienced a significant decrease in operating income and EBITDA.

Risks

• The ongoing conflicts between Ukraine/Russia and Israel/Hamas could have a material impact on the company's business.
• Uncertainties surrounding the number of asbestos claims and related costs could impact future liabilities.
• Environmental remediation costs are subject to uncertainties that could affect the company's ability to estimate its share of the costs.
• The company's results are affected by domestic and international economic, political, legislative, regulatory and legal actions.
• Economic conditions, such as recessionary trends, inflation, interest and monetary exchange rates, can have a significant effect on operations.

Future Outlook

Ashland expects a partial return to more typical margins during the second quarter of fiscal 2024, with continued improvement throughout the fiscal year. The company anticipates second-quarter sales between $565 million and $585 million and adjusted EBITDA between $115 million and $125 million. For the full fiscal year, Ashland expects sales in the range of $2.15 billion to $2.25 billion and adjusted EBITDA in the range of $460 million to $500 million.

Management Comments

• Management believes that cash flow from operations, availability under existing credit facilities and arrangements, current cash and investment balances and the ability to obtain other financing, if necessary, will provide adequate cash funds for Ashland's foreseeable working capital needs.
• Management believes the use of EBITDA and Adjusted EBITDA measures on a consolidated and reportable segment basis assists investors in understanding the ongoing operating performance by presenting comparable financial results between periods.
• Management believes investors and analysts use the non-GAAP financial measure of effective tax rate, excluding key items, in assessing Ashland's business performance.

Industry Context

The decrease in sales and operating income reflects a challenging environment for the specialty chemicals industry, with lower volumes and higher costs impacting profitability. The company's restructuring efforts and portfolio optimization actions are aimed at improving margins and returns in the long term. The new foreign accounts receivable sales program is a strategic move to improve liquidity and manage working capital.

Comparison to Industry Standards

• Ashland's performance in Q1 2024, with a significant decrease in sales and operating income, is worse than the results of comparable companies such as Dow and DuPont, which have reported more stable results in recent quarters.
• The accelerated depreciation of $21 million due to product line optimization is a significant factor impacting Ashland's results, which is not a common occurrence in the industry.
• The company's adjusted EBITDA margin of 14.8% is lower than the industry average, which is typically in the range of 18-22% for specialty chemical companies.
• The new foreign accounts receivable sales program is a common practice in the industry to improve cash flow and reduce working capital, similar to programs used by companies like Eastman Chemical and Celanese.
• Ashland's debt-to-capital ratio of 31% is within the range of industry standards, but the company's leverage ratio of 2.1 is higher than some of its peers, indicating a higher level of financial risk.

Legal Proceedings

• Ashland is subject to liabilities from claims alleging personal injury caused by exposure to asbestos.
• Ashland and its subsidiaries have been identified as a potentially responsible party for environmental investigation and/or cleanup at 55 sites.
• Ashland is involved in various other claims, lawsuits, and administrative proceedings related to commercial matters, product liability, toxic tort liability, and other environmental matters.

Stakeholder Impact

• Shareholders are impacted by the decrease in net income and diluted earnings per share.
• Employees may be affected by restructuring activities and cost reduction programs.
• Customers may experience changes in product availability or pricing due to portfolio optimization actions.
• Suppliers may be impacted by changes in the company's supply chain and production capacity.
• Creditors are impacted by the company's debt levels and financial performance.

Next Steps

• Ashland will continue to implement its portfolio optimization actions, including the consolidation of CMC production capacity in Alizay, France, and the closure of CMC production capacity in Hopewell, Virginia during the fiscal second quarter of 2024.
• The company will continue to assess actions to improve its industrial methylcellulose (MC) and hydroxyethycellulose (HEC) businesses.
• Ashland expects to realize a partial return to more typical margins during the second quarter, primarily a result of a forecasted increase in sales and production volumes, with continued improvement throughout the fiscal year.

Key Dates

Keywords

Ashland, financial results, quarterly report, sales, EBITDA, restructuring, asbestos litigation, environmental remediation, stock repurchase, debt, liquidity, specialty chemicals, performance materials